BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Yano Y, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan. Cancers (Basel) 2021;13:3554. [PMID: 34298768 DOI: 10.3390/cancers13143554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Nakamori K, Yamazaki S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Ohno T, Yano Y, Nishimura K, Tokushige S, Uchimoto T, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H. Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival. Clin Transl Radiat Oncol 2023;39:100558. [PMID: 36545361 DOI: 10.1016/j.ctro.2022.12.001] [Reference Citation Analysis]
2 Ito K, Kita Y, Kobayashi T. Real‐world outcomes of pembrolizumab for platinum‐refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial‐unfit patients. Int J of Urology 2022. [DOI: 10.1111/iju.15101] [Reference Citation Analysis]
3 Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Kimura T, Egawa S, Azuma H. Prognostic value of the fluctuation in the neutrophil–lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 2022;40:344.e11-344.e17. [DOI: 10.1016/j.urolonc.2022.02.012] [Reference Citation Analysis]
4 Shimizu T, Miyake M, Nishimura N, Inoue K, Fujii K, Iemura Y, Ichikawa K, Omori C, Tomizawa M, Maesaka F, Oda Y, Miyamoto T, Sakamoto K, Kiba K, Tanaka M, Oyama N, Okajima E, Fujimoto K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Cancers (Basel) 2022;14:1735. [PMID: 35406508 DOI: 10.3390/cancers14071735] [Reference Citation Analysis]
5 Nishimura K, Nishio K, Hirosuna K, Komura K, Hayashi T, Fukuokaya W, Ura A, Uchimoto T, Nakamura K, Fukushima T, Yano Y, Takahashi N, Nakamori K, Kinoshita S, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Hirose Y, Kimura T, Egawa S, Azuma H. Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer. J Immunother Cancer 2022;10:e003868. [PMID: 35039462 DOI: 10.1136/jitc-2021-003868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Huang CY, Tsai HW, Liu CY, Liu TH, Huang HL, Chang CC, Chen WC, Sun JT. The predictive and prognostic role of hematologic and biochemical parameters in the emergency department among coronavirus disease 2019 patients. Chin J Physiol 2021;64:306-11. [PMID: 34975124 DOI: 10.4103/cjp.cjp_77_21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]